Skip to main content

Is Gilead a good investment today?

June 21, 2024

We bought shares in Gilead Sciences, Inc (Nasdaq: GILD) yesterday because the pharmaceutical announced a supposed breakthrough in HIV Prevention. The stock price had already climbed 9% by the time we bought in. Today, the stock gained 3%, which is solid for one day and beat the overall market handsomely. By next week, we expect another 5% increase and will be time to exit the short term speculative position.

Gilead Sciences, Inc. announced promising results from a trial study of its HIV-1 capsid inhibitor, lenacapavir. The twice-yearly injectable drug demonstrated 100% efficacy in preventing HIV in about 2,000 women tested in South Africa and Uganda. 

The trial's key efficacy endpoints showed lenacapavir's superiority over once-daily oral Truvada® (emtricitabine and tenofovir disoproxil fumarate) and background HIV incidence. Merdad Parsey, MD, PhD, Chief Medical Officer of Gilead, highlighted the potential of lenacapavir as a significant tool in HIV prevention:

    With zero infections and 100% efficacy, twice-yearly lenacapavir has demonstrated its potential as an important new tool to help prevent HIV infections,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. “We look forward to additional results from the ongoing PURPOSE clinical program and continuing toward our goal of helping to end the HIV epidemic for everyone, everywhere.

These are the first data generated from Gilead’s landmark PURPOSE program, which the company describes as the most comprehensive and diverse HIV prevention trial program ever conducted. The PURPOSE program comprises five HIV prevention trials around the world that are focused on innovation in science, trial design, community engagement and health equity.

Summary of Topline PURPOSE 1 Data

PURPOSE 1 Trial Overview:

  • Type: Phase 3, double-blind, randomized study
  • Objective: Evaluate safety and efficacy of twice-yearly subcutaneous lenacapavir for PrEP and once-daily oral Descovy® (emtricitabine and tenofovir alafenamide)
  • Participants: Over 5,300 cisgender women and adolescent girls aged 16-25
  • Locations: 25 sites in South Africa and three in Uganda
  • Groups: Lenacapavir (2,134 participants), Descovy (2,136 participants), Truvada (1,068 participants)
  • Comparison: background HIV and Truvada

Results:

Lenacapavir Group:

  • HIV Incidence: 0 cases (0.00 per 100 person-years)
  • Comparison: Superior to background HIV (2.41 per 100 person-years) and Truvada (1.69 per 100 person-years), with p<0.0001
  • Safety: Well-tolerated, no significant new safety concerns

Descovy Group:

  • HIV Incidence: 39 cases (2.02 per 100 person-years), similar to Truvada
  • Adherence Issues: Challenges with daily pill adherence
  • Safety: Well-tolerated, no new safety concerns

Gilead Sciences, Inc. is a prominent American biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics in areas of unmet medical need. 

Company Overview

  • Name: Gilead Sciences, Inc.
  • Founded: June 22, 1987
  • Founder: Michael L. Riordan, M.D.
  • Headquarters: Foster City, California, USA
  • CEO: Daniel O’Day 
  • Industry: Biotechnology, Pharmaceuticals
  • Stock Symbol: GILD (NASDAQ)

Gilead Sciences primarily focuses on antiviral drugs used in the treatment of:

  • HIV/AIDS
  • Hepatitis B and C
  • Influenza
  • COVID-19
  • Oncology

Notable Products

HIV/AIDS Treatments:

  • Truvada (emtricitabine/tenofovir disoproxil fumarate): A combination antiretroviral drug used for both treatment and pre-exposure prophylaxis (PrEP).
  • Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide): A single-tablet regimen for HIV treatment.
  • Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide): A single-tablet regimen for HIV treatment.

Hepatitis Treatments:

  • Harvoni (ledipasvir/sofosbuvir): An oral treatment for chronic hepatitis C.
  • Epclusa (sofosbuvir/velpatasvir): A combination drug for the treatment of all genotypes of hepatitis C.

COVID-19 Treatment:

  • Veklury (remdesivir): An antiviral drug approved for the treatment of COVID-19.

Oncology:

  • Yescarta (axicabtagene ciloleucel): A CAR T-cell therapy for certain types of large B-cell lymphoma.

Financial Performance

  • Gilead Sciences has been a consistently strong performer in the biotechnology sector, with substantial revenues driven by its blockbuster HIV and hepatitis C drugs. The company invests heavily in research and development to sustain its pipeline of innovative therapeutics.

Challenges and Criticisms

  • Pricing Controversies: Gilead has faced criticism over the pricing of its drugs, particularly its hepatitis C treatments, which have been seen as prohibitively expensive by some healthcare systems.
  • Patent Disputes: The company has been involved in numerous patent disputes and litigation related to its drug formulations and generic competition.

Investment Risk and Short term Outlook

  • Gilead may be significantly overvalued already. Trading at $70 a share, with a market capitalization of $85 billion, GILD is already trading at a super high price to earnings (P/E) ratio of 190. The average P/E ratio for the pharmaceutical industry is 40. 
  • Gilead will announce the results of the next round of studies later in 2024 or in 2025. Market appetite and tolerance for anything short of extraordinary results may be very limited. The stock price can be expected to fall significantly if the results are not perfect. Perfect results may not lead to significant gains because the market seems to have priced perfect results already in the current valuation. 
  • A temporary 5% increase next week may result as late comers and institutional investors ponder the HIV report news. Creatix target rapid sell price is set at $73. 
www.creatix.one

Comments

Post a Comment

Popular posts from this blog

When will the Tesla bubble burst?

December 11, 2024 When will the Tesla bubble burst?  We don't know Fools rush in. It's impossible to know exactly when the Tesla bubble will finally burst. Unfortunately for us at Creatix, we began shorting Tesla too soon. We are down almost 40% on our position as of today. We are not fooling ourselves thinking that we were ever make money on the short position. We truly doubt that Tesla can go down 40% any time soon.  We would love to add to the short position, but it would exceed our $3,000 limit on the stupid bets that we do for fun. We're not Mr. Beast. We have a very limited budget for ridiculousness. We would love to short Tesla tomorrow morning at the ridiculous share price of $424. Tesla is trading at an incredible 116 times earnings, which gives Tesla a market capitalization of $1.32 Trillion. Elon Musk added today $13.4 billion to his fortune. Yes, $13 billion in one day. Yesterday, he had added $11 billion. Yes, that's $24 billion in 2 days.  Six months ago, ...
Post a Comment
Read more

Will Tariffs Reduce the National Debt?

Creatix / June 30, 2025 The U.S. national debt has surpassed $34.7 trillion , and the cost of servicing that debt— just the interest payments—has soared to over $1 trillion annually as of mid-2025. This marks a historic shift: we now spend more just paying interest on the National debt than on defense, Medicare, or any single discretionary program. Economists warn that unless fiscal policy changes, interest costs will crowd out critical investments in infrastructure, education, and innovation, deepening the structural debt burden for future generations. From Osama to MAGA OBBA: the path to U.S. bankruptcy. Osama Bin Laden "succeeded" in putting us in a path to bankruptcy. The U.S. national debt began to increase dramatically after 9/11, marking a sharp departure from the budget surpluses of the late 1990s. In response to the terrorist attacks, the U.S. launched costly wars in Afghanistan and Iraq, while also implementing sweeping tax cuts under the Bush administration. These...
Post a Comment
Read more

How TikTok can Artificially Spread Socialism in America?

Creatix / June 29, 2025 TikTok's Socialist Movement in New York City  In one of the most unexpected political turns in recent New York history, Zohran Mamdani , the democratic socialist Assemblymember from Queens, has defeated former Governor Andrew Cuomo in the Democratic primary for New York City mayor. While the general election remains to be decided in November of this year, Mamdani is now the clear frontrunner. His socialist victory signals not just a generational shift, but the rise of a new kind of political power: one fueled by TikTok , a Chinese-owned social media platform that has become Gen Z’s ideological training ground. From Astoria to Citywide Dominance Mamdani first rose to prominence as a bold and principled advocate for tenants’ rights, public transportation reform, and wealth redistribution in the State Assembly. But his stunning mayoral primary win wasn’t just about policy—it was about algorithmic delivery powered by Chinese media company. Mamdani didn’t r...
Post a Comment
Read more